Results 31 to 40 of about 736 (88)

External validation of a multiple sclerosis treatment decision score using data from the ProVal-MS cohort study. [PDF]

Ther Adv Neurol Disord
Buchka S, Hapfelmeier A, Kirschke JS, Steuerwald V, Naumann M, Soto-Rey I, Rohr SO, Kramer F, Behrens L, Oswald E, Kümpfel T, Zimmermann H, Hoffmann VS, Hagedorn M, Albashiti F, Krumbholz M, Ziemann U, Kohlbacher O, Sailer B, Braunmüller V, Biergans S, de Arruda Botelho Herr M, Ernemann U, Bürkle E, Bender B, Daul A, Ruff C, Römhild J, Wiestler B, Sepp D, Spengler H, Pallaoro P, Boeker M, Kohlmayer F, Dehmelt V, Berthele A, Mühlau M, Uibel P, Wauschkuhn J, Kuhn K, Senel M, Vardakas I, Taranu D, Kestler HA, Sollmann N, Irmak Ön B, Bilger S, Mansmann U, Bayas A, Havla J, Kowarik MC, Tumani H, Hemmer B, ProVal-MS Study Group.   +53 more
europepmc   +1 more source

Long-term immune recovery under continuous antiretroviral therapy (ART) among ART-naive people living with HIV in two cohorts in Germany. [PDF]

Infection
Koppe U, Pörtner K, Kollan C, Pantke A, Sailer A, Dehmel K, Esser S, Jensen BO, Rockstroh JK, Schäfer G, Schürmann D, Stoll M, Wasmuth JC, Kurth T, Gunsenheimer-Bartmeyer B, HIV-1 Seroconverter Cohort and the ClinSurv-HIV Cohort.   +15 more
europepmc   +1 more source

Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disorders. [PDF]

Neurol Res Pract
Tkachenko D, Ayzenberg I, Schöppe LM, Schülke R, Paul F, Duchow A, Bellmann-Strobl J, Siebert N, Kümpfel T, Havla J, Pellkofer H, Jarius S, Wildemann B, Berthele A, Klotz L, Pawlitzki M, Gingele S, Schreiber-Katz O, Weber MS, Senel M, Stellmann JP, Häußler V, Aktas O, Ringelstein M, Hellwig K, Schwake C, Kleiter I, Trebst C, Hümmert MW, Neuromyelitis Optica Study Group (NEMOS)§.   +29 more
europepmc   +1 more source

Author response to Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database. [PDF]

Ther Adv Neurol Disord
Shirani A, Cross AH, Stuve O.
europepmc   +1 more source

Applying two approaches to detect unmeasured confounding due to time-varying variables in a self-controlled risk interval design evaluating COVID-19 vaccine safety signals, using myocarditis as a case example. [PDF]

Am J Epidemiol
Bots SH, Belitser S, Groenwold RHH, Durán CE, Riera-Arnau J, Schultze A, Messina D, Segundo E, Douglas I, Carreras JJ, Garcia-Poza P, Gini R, Huerta C, Martín-Pérez M, Martin I, Paoletti O, Bissacco CA, Correcher-Martínez E, Souverein P, Urchueguía-Fornes A, Villalobos F, Sturkenboom MCJM, Klungel OH.   +22 more
europepmc   +1 more source

Genetic contribution to severe COVID-19 in adults under 60 years without major comorbidities in the German National Pandemic Cohort Network (NAPKON). [PDF]

Hum Genomics
Abolhassani A, Alawathurage TM, Schmidt A, Brand F, Kilarski LL, Altmann H, Dahl E, Frank S, Göpel S, Hanses F, Hellmuth JC, Herr C, Kaasch AJ, Kobbe R, Konik MJ, Pink I, Römmele C, Rupp J, Scheer CS, Schneider MA, Stellbrink C, Stubbe HC, Tepasse PR, Teufel A, Vadász I, Vehreschild MJGT, Witzenrath M, Anton G, Bröhl I, Herold S, Illig T, Jiru-Hillmann S, Krawitz P, Mitrov L, Philipsen A, Pütz SM, Noethen MM, Nuernberg P, Reese JP, Riess O, Schreiber S, Schultze J, Steinbeis F, Vehreschild JJ, Wildberg C, Ludwig KU, Schulte EC.   +46 more
europepmc   +1 more source

Tysabri Observational Program (TOP): long-term safety and effectiveness of natalizumab treatment in relapsing-remitting multiple sclerosis over 15 years. [PDF]

J Neurol Neurosurg Psychiatry
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Greco A, Sun Z, Lasky T, TOP Investigators.   +8 more
europepmc   +1 more source

Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study. [PDF]

Clin Infect Dis
Ford SL, Felizarta F, Han K, Wang K, Crauwels H, Dari A, Masia M, Garcia Deltoro M, Degen O, Angel JB, Hsiao CB, Acuipil C, Kolobova I, Harrington C, Rimler K, Spreen W, D'Amico R.   +16 more
europepmc   +1 more source

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. [PDF]

J Clin Oncol
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H, German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators, German-speaking Myeloma Multicenter Group (GMMG) HD7.   +38 more
europepmc   +1 more source

SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma. [PDF]

Oncologist
Janssen JBE, Iyer KK, Gerritse SL, Janssen E, Gootjes EC, Labots M, Buffart TE, Wumkes ML, Douma JAJ, Streppel MM, Buffart LM, Jonker MA, van den Hombergh E, van Erp NP, Medema JP, Tauriello DVF, Poel D, Verheul HMW.   +17 more
europepmc   +1 more source